Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 11:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 1,820 matching trials from the live ClinicalTrials.gov search.
Conditions
Breast Cancer, Colorectal Cancer, Endometrial Cancer, Kidney Cancer, Multiple Myeloma, Ovary Cancer, Prostate Cancer, Thyroid Cancer, Non-Hodgkin Lymphoma
Interventions
Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health, Diet-Exercise, Exercise-Diet, Combined Diet and Exercise
Behavioral · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years and older
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Birmingham, Alabama • Memphis, Tennessee
Conditions
Renal Cancer, Melanoma
Interventions
Aldesleukin, Sorafenib
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Kidney Cancer
Interventions
tanespimycin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
New York, New York
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions
filgrastim, cisplatin, doxorubicin hydrochloride, gemcitabine hydrochloride, ifosfamide, paclitaxel
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
New York, New York
Conditions
Metastatic Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Advanced Gastric Adenocarcinoma, Metastatic Colorectal Adenocarcinoma
Interventions
ibrutinib, everolimus, paclitaxel, docetaxel, cetuximab, pembrolizumab
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
44
States / cities
Huntsville, Alabama • Gilbert, Arizona • Tucson, Arizona + 39 more
Conditions
Benign Kidney Neoplasm, Kidney Neoplasm, Renal Cell Cancer
Interventions
Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging, Hyperpolarized 13C,15N2-urea
Drug · Procedure
Lead sponsor
Zhen Wang, MD
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
San Francisco, California
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
Interventions
Biospecimen Collection, cfDNA or ctDNA Measurement, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration, Relatlimab
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
992 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
495
States / cities
Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 374 more
Conditions
Kidney Cancer
Interventions
PEG-interferon alfa-2b, GM-CSF, thalidomide
Biological · Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Kidney Cancer
Interventions
recombinant interferon alfa, thalidomide
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
11
States / cities
Scottsdale, Arizona • South Bend, Indiana • Des Moines, Iowa + 6 more
Conditions
Renal Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Ovarian Neoplasms
Interventions
RO7515629, tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Denver, Colorado • Nashville, Tennessee
Conditions
Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor, Melanoma, Hepatoblastoma, Hepatocellular Carcinoma, Neuroblastoma, Wilms Tumor
Interventions
Cryoablation Therapy, Nivolumab, Ipilimumab
Procedure · Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
1 Year to 39 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Kidney Cancer
Interventions
gefitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
New York, New York
Conditions
Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer, CRC, NSCLC, Pancreas Cancer, Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Mesothelioma, Malignant, Mesothelioma; Lung, Cancer, Triple Negative Breast Cancer (TNBC), Renal Cell Carcinoma (Kidney Cancer), Head and Neck Squamous Cell Carcinoma HNSCC
Interventions
Apheresis, Next Generation Sequencing (NGS), Long Range NGS HLA typing
Other · Diagnostic Test
Lead sponsor
A2 Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
16
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 13 more
Conditions
Cancer, Chronic Obstructive Pulmonary Disease, Heart Failure, Dementia, End Stage Liver Disease, End Stage Renal Disease, Neuromuscular Diseases
Interventions
Tech-supported HBPC, Standard HBPC
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
3,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Pasadena, California • Portland, Oregon
Conditions
Cancer
Interventions
captopril, cyclophosphamide, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Carcinoma, Renal Cell, Lymphoma, Non-Hodgkin
Interventions
SGN-75
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
9
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 6 more
Conditions
Kidney Cancer
Interventions
therapeutic allogeneic lymphocytes, sunitinib malate
Biological · Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New Brunswick, New Jersey
Conditions
Sarcomas, Melanomas, Germ Cell Tumors, Epithelial Malignancies (Excluding Lung and Renal Cell Carcinomas), Pulmonary Metastases
Interventions
AeroEclipse II Breath Actuated Nebulizer, Bintrafusp alfa, Azacytidine
Device · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Prostate Cancer, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Head and Neck Cancer, Bladder Cancer, Non-small Cell Lung Cancer
Interventions
MGA271
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
12
States / cities
Los Angeles, California • New Haven, Connecticut • Tampa, Florida + 7 more
Conditions
Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Endocervical Cancer, Squamous Cell Carcinoma of Head and Neck, Bladder Urothelial Cancer, Colorectal Carcinoma, Esophageal Cancer, Ovarian Cancer, Renal Cell Carcinoma, Prostate Cancer, Melanoma, Mesothelioma, Cholangiocarcinoma
Interventions
NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Gilbert, Arizona • Los Angeles, California • Sarasota, Florida + 6 more
Conditions
Renal Cancer, Non Small Cell Lung Cancer (NSCLC), Soft Tissue Sarcoma
Interventions
Panobinostat (LBH589), Sorafenib
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Metastatic Renal Cell Carcinoma
Interventions
NST using MUD for metastatic renal cell carcinoma
Procedure
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • Minneapolis, Minnesota + 2 more
Conditions
ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Hypoxia, Renal Cell Carcinoma, Hypoxia Inducible Factor (HIF), HIF2α Inhibitor, Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha), Hypoxia Inducible Factor 2α (HIF-2α), Clear Cell
Interventions
Oral NKT2152
Drug
Lead sponsor
NiKang Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
13
States / cities
Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 10 more
Conditions
Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage IV Renal Cell Cancer AJCC v7
Interventions
Bevacizumab, Biopsy, Ipilimumab, Laboratory Biomarker Analysis, Metastasectomy, Nivolumab, Therapeutic Conventional Surgery
Biological · Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Houston, Texas